Detection of benzo[a]pyrene-diol-epoxide-DNA adducts in white blood cells of psoriatic patients treated with coal tar

Mutat Res. 1992 Jan;281(1):11-6. doi: 10.1016/0165-7992(92)90030-l.

Abstract

An enzyme-linked immunosorbent assay (ELISA) was used to detect BPDE-DNA adducts in white blood cells of 23 psoriatic patients undergoing clinical coal tar therapy. Ten of these patients were reanalyzed 2-5 months after the end of the coal tar treatments. The results show that the mean adduct level during the treatment period was 0.26 +/- 0.16 fmole BPDE/micrograms DNA (7.7 +/- 4.9 adducts/10(8) nucleotides), while 2-5 months later the mean adduct level had decreased significantly (P less than 0.005) to 0.11 +/- 0.08 fmole BPDE/micrograms DNA (3.3 +/- 2.4 adducts/10(8) nucleotides). No relationship could be ascertained between the level of exposure and the amount of BPDE-DNA adducts. In addition, no difference in the level of DNA adducts was found between smoking and non-smoking patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analysis of Variance
  • Benzo(a)pyrene / metabolism*
  • Coal Tar / pharmacology*
  • DNA / metabolism*
  • DNA Adducts*
  • DNA Damage*
  • Dose-Response Relationship, Drug
  • Enzyme-Linked Immunosorbent Assay
  • Follow-Up Studies
  • Humans
  • Leukocytes / drug effects*
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / genetics
  • Reproducibility of Results
  • Smoking / adverse effects

Substances

  • DNA Adducts
  • benzo(a)pyrene-DNA adduct
  • Benzo(a)pyrene
  • Coal Tar
  • DNA